Enliven Therapeutics ELVN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -26.6%+4.7pp | -27%+5.1pp | -25.4%— | -25.3%— | -31.3%— | |
| Liquidity | ||||||
| Current ratio | 40.3×+19.3× | 28.7×+8.7× | 32.9×+15.5× | 32.6×+18.2× | 21.1×+7.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $7.22+25.3% | $8.11+23.2% | $7.67+28.3% | $9.37+47.8% | $5.76-23.8% | |
| Valuation | ||||||
| Market capitalization | $2.34B+143% | $913.95M-16.9% | $1.21B-1.6% | $1.25B+11.1% | $964.41M+30.4% | |
| Price / book | 5.2×+1.8× | 2×-1.6× | 2.5×-1.7× | 2.6×-1.1× | 3.3×+1.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Enliven Therapeutics's ratios come from?
- Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.